Articular Cartilage Treatment with Injectable hydrogel is Valuable and long-term Effective

European Innovation CouncilHORIZON-EIC-ACC-BFID: 190135342
EC Contribution
€25,000
Consortium Size
1 orgs
Start Year
2022
Summary

Hy2Care brings a regenerative Injectable Hydrogel, of joint- and cartilage-mimicking composition, that is used to treat damaged cartilage. The cartilage defects are easily filled with a syringe during a standard one time arthroscopy. The hydrogel fill the defect, prevents ingrowth of scar tissue and allows the body to heal itself by creating true Hyaline cartilage, ensuring an optimal regenerated tissue. The high-quality regeneration provides the basis for a long lasting repair, postponing or even preventing the onset of osteoarthritis. The gel binds covalently to the surrounding cartilage ensuring integration of the new tissue. Revalidation is fast as the cartilage regrowth follows the degradation of the gel. The lasting repair not only prevents additional secondary treatments but also pain, disability and escalating follow-on costs. In submission of the last cut off of the EIC in october 2020 Hy2Care scored a 14.0 and recieved the seal of excellence.

Consortium (1)